Arrowhead to Webcast Analyst Day Presentation on Hepatitis B Candidate ARC-520

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. CVS
9. SPY
10. XYZ

Go back to Arrowhead to Webcast Analyst Day Presentation on Hepatitis B Candidate ARC-520

Arrowhead Research (ARWR) Announces Nomination of ARC-HIF2 Unsing Extrahepatic DPC System

September 11, 2015 7:34 AM EDT

Arrowhead Research (NASDAQ: ARWR) announced that it has nominated ARC-HIF2 as its first therapeutic candidate delivered using a new Dynamic Polyconjugate (DPC) designed to target tissues outside of the liver. Arrowhead believes that ARC-HIF2, which uses RNA interference to silence transcription factor hypoxia-inducible factor 2 (HIF-2), is a promising new candidate for the treatment of clear cell renal cell carcinoma (ccRCC). The company will present preclinical data at the European Cancer Congress 2015 (ECC2015) in Vienna on September 27 in a session starting at 16:45 CEST. In a poster titled HIF-2 targeting with a novel RNAi delivery platform as... More